GlassScriptPhysician profile
Michael G Spaeder
NPI 1194064923
$2,082.87
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $237 · 2022: $102 · 2023: $1,683 · 2024: $60.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,743.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $657.89 | 2021-2023 | |
| Glaxosmithkline, LLC. | $282.11 | 2023 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $234.62 | 2023 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $222.02 | 2023 | Mounjaro, Emgality, Jardiance |
| Pfizer INC. | $86.73 | 2021-2023 | |
| Exact Sciences Corporation | $84.01 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $75.81 | 2022-2023 | Farxiga, Breztri |
| Supernus Pharmaceuticals, INC. | $64.72 | 2023-2024 | Qelbree |
| Merck Sharp & Dohme LLC | $55.07 | 2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Amgen INC. | $53.53 | 2023-2024 | Repatha, Otezla |
| Daiichi Sankyo INC. | $49.37 | 2023 | Injectafer |
| Axsome Therapeutics, INC. | $41.00 | 2023 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $34.07 | 2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.54 | 2023 | Tradjenta, Jardiance, Synjardy |
| E.R. Squibb & Sons, L.L.C. | $26.11 | 2023 | Eliquis |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $23.57 | 2023 | Loreev Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.20 | 2023 | Trulance, Xifaxan |
| Dexcom, INC. | $16.30 | 2021 | |
| Cequr Corporation | $14.68 | 2024 | Cequr Simplicity |
| Nabriva Therapeutics, Plc | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Spaeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.